Cancer clinical trials in the region Île-de-France
684 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Prostate cancer
#NCT07226986
#2025-521859-23-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
4 recruiting sites
Novartis
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 3
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 2
Required histologic types
Hodgkin lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
3 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 2 Cohorte 1
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 1
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Acute leukemia
#NCT04811560
Phase 2
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2
Acute leukemia
#NCT04811560
Phase 1
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
Other mutation
KMT2A
NPM1
NUP214
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2
Breast cancer
#NCT07100106
#2025-521128-31-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
5 recruiting sites
Genentech, Inc
Phase 1 / Phase 2
Stomach and esophageal cancer
#NCT06469944
#2023-509307-33-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Stomach and esophageal cancer
Sarcoma and GIST
#NCT05957367
#2024-516476-15-00
Module B Partie 2
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KIT
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Deciphera Pharmaceuticals, LLC